Biographical Sketch

Stewart Lyman, Ph.D, has 30 years’ experience in research and biotechnology. In 2004 he started Lyman BioPharma Consulting LLC to offer two primary services: (1) advice on how to set up and run successful collaborations with outside investigators, either academic or in industry; (2) technology and science assessment, with a special focus on developing agonists and antagonists for tyrosine kinase and other receptors.

Dr. Lyman joined Immunex Corporation in 1988 as a molecular biologist and continuously assumed greater scientific responsibility during his 14 year tenure. Within a year of joining the company he initiated the largest research project in Immunex's history, Receptors in Search of Ligands (RISOL). The RISOL project cloned eight unique cytokines/growth factors, thanks to Dr. Lyman’s insight that cloned receptors could be used as tools to identify their unknown ligands. Subsequently Dr. Lyman chaired numerous projects at Immunex in signal transduction, molecular biology, and hematology/oncology.

Dr. Lyman has cloned several growth factors, including Ephrin B1 and human TSLP, and has identified ligands for CD7, CD44, and the c-kit tyrosine kinase receptor. His most significant scientific accomplishment was cloning flt3 ligand, an early acting hematopoietic growth factor and key regulator of dendritic cell proliferation. After designing the clinical form of flt3, he helped lead flt3 into clinical trials for stem cell mobilization and cancer immunotherapy.

In 1998, Dr. Lyman joined the Immunex Scientific Management Team as Director of Extramural Research, and for the next four years ran the largest extramural research program in the United States. His group managed more than 2500 research collaborations, shipping over 1000 distinct reagents to over 1000 scientific and industrial groups at institutions worldwide. He was also responsible for the initial review of all in-licensing opportunities. As Director, he developed an innovative system for timely collection, distribution, and storage of data from collaborators, and his emphasis on inspecting collaborators’ data for intellectual property opportunities significantly expanded Immunex’s patent portfolio.

Dr. Lyman holds 21 U.S. patents and has authored or co-authored 129 scientific publications. He has been invited to give presentations about cytokines and their receptors at numerous national and international meetings. He served on the scientific advisory board of Modern Drug Discovery magazine and is a member of the AAAS.

Dr. Lyman received his B.S. degree from the State University of New York at Albany and his Doctorate in Oncology from the McArdle Laboratory for Cancer Research at the University of Wisconsin-Madison. Prior to joining Immunex he conducted postdoctoral research at the Fred Hutchinson Cancer Research Center in Seattle.